Metamark is leading a shift in urological cancer care to enable patients and their physicians to make informed tretment decisions that lead to better quality of life and lower cost of care.

LEARN MORE

Press Release

METAMARK GENETICS INITIATES CLINICAL USE OF ProMark™

Metamark Genetics, Inc. today announced that it has initiated clinical use of the company’s ProMark™ prognostic test to help guide the medical management of patients with early-stage prostate cancer.

read article
Press Release

Metamark Announces Appointment of Dr. Peter Blume-Jensen to its Scientific Advisory Board

Metamark today announced that its Chief Scientific Officer, Peter Blume-Jensen, M.D., Ph.D., will be joining a targeted therapeutics startup, and will continue working for Metamark as a member of the company’s Scientific Advisory Board and as a consultant.

read article
Displaying results 9-10 (of 12)
 |<  <  1 - 2 - 3 - 4 - 5 - 6  >  >|